Cadrenal Therapeutics
CVKD
20 hedge funds and large institutions have $452K invested in Cadrenal Therapeutics in 2026 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
0% more funds holding
Funds holding: 20 → 20 (0)
1.96% less ownership
Funds ownership: 5.85% → 3.89% (-2%)
45% less capital invested
Capital invested by funds: $824K → $452K (-$372K)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$49.8K |
| 2 |
BlackRock
New York
|
+$13.8K |
| 3 |
CCA
Cygnus Capital Advisors
Atlanta,
Georgia
|
+$10.5K |
| 4 |
DWP
Destiny Wealth Partners
Tavares,
Florida
|
+$1.4K |
| 5 |
Citigroup
New York
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$171K |
| 2 |
LPL Financial
San Diego,
California
|
-$88.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$7.3K |
| 4 |
Morgan Stanley
New York
|
-$6.87K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.4K |
CVKD Hedge Fund Activity: Q1 2026 in Review
20 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Cadrenal Therapeutics (CVKD) for Q1 2026, worth a combined $452K — down 45% from $824K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CVKD positions and 4 closed out — a net gain of 1 holder — while 2 added to existing stakes and 5 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $49.8K. The largest seller was DRW Securities, exiting entirely with an estimated $171K sold.
- 20 institutional investors held Cadrenal Therapeutics (CVKD) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $452K of Cadrenal Therapeutics stock for Q1 2026, down 45% quarter-over-quarter.
- 5 funds opened new Cadrenal Therapeutics positions in Q1 2026 and 4 closed out, a net change of +1 holder.
- The largest Cadrenal Therapeutics buyer in Q1 2026 was Geode Capital Management, an estimated $49.8K added.
- The largest Cadrenal Therapeutics seller in Q1 2026 was DRW Securities, an estimated $171K sold.
Based on aggregated 13F filings for Q1 2026.